Study of Oglemilast for the Treatment of Asthma

Forest Laboratories

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Placebo then Oglemilast; Drug: Oglemilast

Study type: Interventional

Funder types: Industry

Identifiers

NCT00322686

GRC-MD-03

Details and patient eligibility

About

The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.

Enrollment: 6 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild atopic asthma
• Hyperreactivity to methacholine
• Exhibit positive response to standard allergen skin prick test

Exclusion criteria

• Pulmonary disease other than asthma
• Asthma exacerbation within 4 weeks
• History of substance abuse
• Active cardiac disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

6 participants in 2 patient groups

Oglemilast followed by placebo

Experimental group

Treatment:

Drug: Oglemilast

Placebo followed by Oglemilast

Experimental group

Treatment:

Drug: Placebo then Oglemilast